Drug safety alert: Adverse reactions linked to Colistimethate Sodium flagged by Indian Pharmacopoeia Commission

Published On 2023-08-01 12:14 GMT   |   Update On 2023-08-01 12:14 GMT

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of July, has revealed that Colistimethate Sodium, an antibiotic indicated for the treatment of infections caused by susceptible strains of certain gram-negative bacilli is linked with adverse drug reactions (ADRs) named Bartter's like Syndrome.This came after a preliminary analysis of...

Login or Register to read the full article

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of July, has revealed that Colistimethate Sodium, an antibiotic indicated for the treatment of infections caused by susceptible strains of certain gram-negative bacilli is linked with adverse drug reactions (ADRs) named Bartter's like Syndrome.

This came after a preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Colistimethate is an antibiotic indicated for the treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa.

For more details check out the link given below:

Drug Safety Alert: Indian Pharmacopoeia Commission Flags Adverse Reactions Linked To Colistimethate Sodium

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News